Pharma News

The proposal, notified through Gazette Notification G.S.R. 861(E), dated 28 September 2026, seeks to extend advertising restrictions for medicines listed under Schedule H, Schedule H1 and Schedule X to entities holding licences for the sale and distribution of drugs.

Zydus Lifesciences Limited and Formycon AG have announced that the US Food and Drug Administration (USFDA) has accepted the Biologics License Application (BLA) for FYB206, a proposed biosimilar to Keytruda® (pembrolizumab), for review.

A new review in Genes & Diseases highlights FTO, an enzyme involved in RNA modification, as a potentially important biomarker and therapeutic target across gastrointestinal cancers. The article brings together current understanding of FTO in gastric, liver, colorectal and pancreatic cancers, revealing a complex role in which the enzyme can both promote and suppress cancer progression depending on biological context.

A survey of 539 people with Lynch syndrome highlights a gap between evidence supporting aspirin-based cancer prevention and its implementation in clinical practice, despite strong interest in preventive research.

Rubicon Research Limited has received one observation in a Form 483 issued by the United States Food and Drug Administration (US FDA) following an unannounced inspection of its manufacturing facility in Satara, Maharashtra.

Solid tumors are not merely collections of malignant cells but complex ecosystems comprising tumor cells, stromal cells, and the extracellular matrix (ECM). The tumor microenvironment (TME) fosters immunosuppression through tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), regulatory T cells (Tregs), and cancer-associated fibroblasts (CAFs), while physical barriers such as dense ECM and abnormal vasculature hinder drug penetration

The U.S. Food and Drug Administration (FDA) has approved HOVILPRI (pritelivir) tablets for the treatment of mucocutaneous lesions caused by herpes simplex virus (HSV) infection in immunocompromised adults whose infections have not responded to standard antiviral treatments.

Viatris Inc. has agreed to acquire Pacira BioSciences Inc. in an all-cash transaction valued at approximately 1.65 billion USD, marking a significant step in its strategy to expand its innovative medicines business.

Pfizer has announced that the US Food and Drug Administration (FDA) has approved TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment.